AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00415103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
Study NCT02592174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health related quality of life and social and demographic informations
Description: At the inclusion visit with a self-assessment questionnaire
Study NCT02592174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurocognitive assessment
Description: At the neurocognitive visit, with standard test as CONSTANCES cohort
Study NCT02592174 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: cerebral images sub-study
Description: Standard magnetic resonance imaging
Study NCT01486628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ND0612
Description: levodopa and carbidopa solution for subcutaneous administration
Study NCT01486628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for SC continuous administration
Study NCT02174055 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Interviews
Description: participate in a brief interview
Study NCT02174055 — intervention group
Intervention type: BEHAVIORAL
Intervention: newly developed questionnaire
Description: 10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
Study NCT02174055 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pilot Testing the Draft Measure
Description: The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
Study NCT00913367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride + insulin glargine (Amaryl + Lantus)
Description: * Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Study NCT00913367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
Description: * Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Study NCT04902456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Power chain and Crimpable hook fro En-masse Retraction
Description: Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew
Study NCT04902456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-loop
Description: closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
Study NCT03366402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR H1N1
Description: At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
Study NCT05309564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Single intervention
Study NCT03523975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
Study NCT03523975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
Study NCT03523975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
Study NCT04243187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chilean Native Beans
Description: In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey).
Study NCT00528398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00528398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT01408914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-Dose Rifampin
Description: The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
Study NCT00819351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Asparaginase at six weeks interval
Description: PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
Study NCT00819351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG Asparaginase at two weeks interval
Description: PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
Study NCT03417453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drop Dispenser TYPE Opticare
Description: Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners.
Study NCT03417453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drop Dispenser Autodrop
Description: Eye Drop Dispenser Autodrop
Study NCT02730325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin/protein isolate (SBI)
Study NCT02730325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02158338 — intervention group
Intervention type: OTHER
Intervention: Asthma
Description: mothers who have children that have been diagnosed with respiratory issues
Study NCT02158338 — intervention group
Intervention type: OTHER
Intervention: Non-asthma
Description: mothers who have children that do not have a diagnosis of respiratory problems
Study NCT03688477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
Study NCT02395900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed
Study NCT02395900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Study NCT04127331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.
Study NCT01435109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Behavioral Intervention for OA
Description: Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
Study NCT01435109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Intervention for OA
Description: Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
Study NCT01435109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Patient and Provider Interventions for OA
Description: Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
Study NCT04797793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.1%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT04797793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT04797793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin® Gel (Adapalene 0.1%, Galderma)
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study NCT01748643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep neuromuscular blockade with rocuronium, reversal with sugammadex
Description: after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio > 0.9.
Study NCT01748643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine
Description: After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is > 0.9.
Study NCT03954951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodality behavioral strategy
Description: * On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province.
Study NCT01341964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600mg (2 pills)
Study NCT01341964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600mg (2 pills)
Study NCT01341964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325mg (1 pill)
Study NCT01341964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg (1 pill)
Study NCT03141242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ENACT group visit
Description: Participation in two 2 hour group visits about advance care planning.
Study NCT03141242 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mailed Resources
Description: Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
Study NCT01673451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Description: Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
Study NCT01673451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
Study NCT02409459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectafer
Study NCT02409459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study NCT00778089 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ArteFill® Skin Test
Description: Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
Study NCT01904682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rigosertib
Description: Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
Study NCT03641144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation laser
Description: Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
Study NCT03641144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional laser
Description: Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
Study NCT01966640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basophil Activation Test
Description: blood sample for Basophil Activation Test
Study NCT02771158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
Study NCT02771158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered to double blind the study
Study NCT02502539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled physical activity
Study NCT01768481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
Study NCT01768481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo controlled arm receives similarly looking placebo.
Study NCT00827970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening for urogenital Chlamydia trachomatis
Description: Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
Study NCT03610022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with vismodegib
Description: Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
Study NCT05641233 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
Study NCT01172184 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac catheterization
Description: Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
Study NCT01042327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELISIO dialyzer
Description: 3 x week dialysis using ELISIO dialyzer for 12 weeks
Study NCT01042327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresenius FX100 dialyzer
Study NCT00128778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Study NCT00643032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous iliohypogastric
Study NCT00643032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative administration near the nerve
Study NCT04151667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
Study NCT04151667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
Study NCT04151667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Pill
Description: Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance \< 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor.
Study NCT04151667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m\^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
Study NCT04567433 — intervention group
Intervention type: DRUG
Intervention: Hydroxyethyl starch
Description: Hydroxyethyl starch compared to 0.9% saline
Study NCT04567433 — intervention group
Intervention type: DRUG
Intervention: Hydrocortisone
Description: Hydrocortisone compared to Placebo
Study NCT04567433 — intervention group
Intervention type: PROCEDURE
Intervention: Early Goal Directed Therapy
Description: Early Goal Directed Therapy compared to Usual Care
Study NCT03007381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Intravenous analgesic
Study NCT03007381 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Sham comparator
Study NCT03051607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: 1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
Study NCT02567942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol group
Description: Patient will be anesthetized by using propofol infusion during operation
Study NCT02567942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane group
Description: Patient will be anesthetized by using sevoflurane inhalation during operation
Study NCT03946384 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection on the history of the disease, hemophilia